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ABSTRACT
The tribe Proteeae comprises the genera Proteus, Morganella and Providencia. Few studies have
speciﬁcally investigated the epidemiology of infections caused by the Proteeae, and none has been
conducted in a large non-selected population. The present study was a population-based laboratory
surveillance in the Calgary Health Region (population 1.2 million), Canada during 2000–2005 that aimed
to deﬁne the incidence, demographical risk-factors for acquisition and antimicrobial susceptibilities of
Proteeae isolates. In total, 5047 patients were identiﬁed from whom Proteeae isolates were obtained (an
annual incidence of 75.9 ⁄ 100 000), with females and the elderly being at highest risk. Incidence rates
were 64.8, 7.7 and 3.4 ⁄ 100 000 ⁄ year for the genera Proteus, Morganella and Providencia, respectively.
Overall, 85% of infections were community-onset, and the overall rate of bacteraemic disease was
2.0 ⁄ 100 000. Compared with other species, Proteus mirabilis occurred at a much higher frequency,
especially among females, and was less likely to be isolated from hospital-onset infections or to be part
of a polymicrobial infection. Among isolates from community-onset infections, Providencia spp. were
less likely to be from outpatients and more likely to be from nursing home residents. There were low
overall rates of resistance to ciproﬂoxacin (4%) and gentamicin (5%), with Prot. mirabilis generally being
the most susceptible. Members of the Proteeae were isolated frequently in both the community and
hospital settings, but were infrequent causes of invasive disease. The occurrence, demographical
risk-factors and microbiology of Proteeae isolates varied according to the individual species.
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INTRODUCTION
The tribe Proteeae consists of three genera:
Proteus, Morganella and Providencia [1]. These
organisms cause a range of human infections of
different severities, and have been associated with
outbreaks of infection in hospitals and nursing
homes [2–5]. While antimicrobial resistance sur-
veys have revealed that members of the Proteeae
are relatively frequent among clinical isolates, and
a number of series have investigated speciﬁc
subsets of infections caused by these organisms
[6–10], few studies have focused on the Proteeae
as a whole [11]. Kim et al. [11] described 132
episodes of bacteraemia involving Proteeae in a
tertiary-care centre in Korea, with Morganella
morganii being the most frequent isolate (61 cases),
followed by Proteus mirabilis (41) and Proteus
vulgaris (20). However, this study was performed
at a single hospital and was focused solely on
isolates from bacteraemia. The occurrence and
determinants of all tribe Proteeae infections in a
non-selected population remain to be deﬁned.
Population-based studies, in which all incident
cases of a disease occurring in a deﬁned
Corresponding author and reprint requests: K. B. Laupland,
Calgary Laboratory Services, Room 1W-415, #9, 3535 Research
Road NW, Calgary, Alberta T2L 2K8, Canada
E-mail: kevin.laupland@calgaryhealthregion.ca
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
geographical region are studied, minimise selec-
tion bias associated with hospital- or clinic-based
studies [12,13]. The present study describes a
population-based laboratory surveillance for all
Proteeae isolates in a large Canadian health
region, with the aim of deﬁning their incidence,
associated demographical risk-factors and micro-
biological features.
MATERIALS AND METHODS
Study population
The Calgary Health Region (CHR) provides all publicly
funded healthcare services to the 1.2 million residents of the
cities of Calgary and Airdre, as well as numerous adjacent
surrounding communities, together covering an area in Can-
ada of 37 000 km2. Acute care is provided principally by one
paediatric and three major adult hospitals, with c. 2000 acute-
care beds and 100 000 discharges yearly. With the exception of
a few small rural hospitals, all routine microbiological tests for
community and hospital sites in the CHR are performed by
Calgary Laboratory Services. The study included all patients
from whom Proteeae isolates were obtained from specimens
submitted at hospital and community-based collection sites
within the CHR to Calgary Laboratory Services between 1
January 2000 and 31 December 2005. Patients were assumed to
be CHR residents and were included in the analysis if they
were outpatients with Alberta Personal Healthcare numbers
from whom specimens were submitted to CHR-based collec-
tion sites, or if they were admitted to a CHR acute-care facility.
Since laboratory data without personal identiﬁers were studied
and individual clinical records were not reviewed, speciﬁc
institutional ethics review was not required.
Population-based surveillance
Active, population-based surveillance of all Proteeae isolates
from patients in the CHR during the study was performed at
Calgary Laboratory Services. Hospitals, nursing homes,
physicians’ ofﬁces and community collection sites were includ-
ed in the surveillance. Following identiﬁcation of Proteeae
isolates, basic laboratory and demographical data were
obtained from the regional laboratory information system
(PathNet Classic v.306; Cerner, Kansas City, MO, USA).
Community-onset isolates were deﬁned as isolates submitted
from community-based collection sites or nursing homes, or
obtained within 2 days of admission to an acute-care facility;
hospital-onset isolates were those isolated >2 days after
hospital admission. In order to minimise the bias associated
with repeated culturing of specimens from the same episode of
clinical disease, only one culture ⁄patient ⁄ species ⁄ year was
included in the assessment of incident cases.
Clinical laboratory testing
Proteeae isolates were obtained using standard techniques;
identiﬁcation and susceptibilities to antimicrobial agents were
determined using the Vitek-Legacy system (Vitek AMS;
bioMe´rieux Vitek Systems Inc., Hazelwood, MO, USA) with
customised antimicrobial susceptibility testing cards, and were
interpreted according to CLSI criteria [14]. At Calgary Labor-
atory Services, identiﬁcation is performed routinely to the
species level on all clinically relevant isolates, but individual
speciation and antimicrobial susceptibility testing is occasion-
ally not performed on some non-invasive isolates. In the
present study, intermediately-susceptible results were
grouped with and reported as resistant; when susceptibility
test results were not available, rates were reported using the
number actually tested as the denominator. Bacteraemia was
deﬁned by the isolation of Proteeae strains from at least one set
of blood cultures. Polymicrobial episodes were those in which
non-Proteeae strains were co-isolated from a single clinical
specimen.
Statistical analysis
All analyses were performed using Stata v.9.0 (Stata Corp.,
College Station, TX, USA). Differences in proportions among
categorical data were assessed using Fisher’s exact test.
Medians with inter-quartile range (IQR) were used to describe
asymmetrically distributed continuous variables. Incidence
rates were calculated using regional demographical data as the
denominator. Category-speciﬁc risks were calculated and
reported as risk ratios (RRs) with exact 95% CIs, as described
previously [15].
RESULTS
During the 6-year surveillance period, 6527 Pro-
teeae isolates were obtained from 6466 clinical
specimens from 4495 CHR residents. The overall
annual population incidence of Proteeae isolation
was 5047 episodes, or 75.9 ⁄ 100 000 population;
the rates for Proteus, Morganella and Providencia
were 64.8, 7.7 and 3.4 ⁄ 100 000, respectively.
Bacteraemia occurred in 134 patients (110
community-onset; 82%), giving an incidence rate
of 2.0 ⁄ 100 000 ⁄ year. The majority (4290 of 5047;
85%) of incident Proteeae isolates were commu-
nity-onset, with 803 (19%) from emergency
departments or inpatients within 2 days of admis-
sion, 970 (23%) from nursing homes, and 2517
(59%) from outpatients. Hospital-onset isolates
were identiﬁed a median of 12 (IQR 6–29) days
after admission to an acute-care hospital.
The median age of patients with Proteeae
isolates was 69.6 (IQR 41.6–81.8) years, and 3460
(69%) were female. There was a signiﬁcant
relationship between age, gender and the inci-
dence of isolation, with the rates increasing
dramatically above the age of 60 years (Fig. 1).
Overall, females had twice the risk of isolation of
Proteeae relative to males (103.8 vs. 47.8 ⁄ 100 000;
RR 2.17; 95% CI 2.04–2.30; p <0.0001), and this
excess risk was observed across all age groups,
with the exception of those aged <10 years
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(Fig. 1). Compared with males, females were
signiﬁcantly less likely to have hospital-onset
isolates (453 ⁄ 3460; 13% vs. 304 ⁄ 1587; 19%;
RR 0.68; 95% CI 0.60–0.78; p <0.0001). As with
the overall isolation rate, the incidence of bacter-
aemia also increased signiﬁcantly with increased
age (Fig. 2). In contrast, no excess risk of Proteeae
bacteraemia was revealed for females when com-
pared with males (1.5 vs. 1.7 ⁄ 100 000; RR 0.89;
95% CI 0.59–1.32; p 0.6).
Among the entire collection of 6527 isolates, the
most common specimen type was urine (5590,
85.6%), followed by wounds ⁄ soft-tissue speci-
mens (474, 7.3%), blood (214, 3.3%), miscellane-
ous ﬂuids (150, 2.3%) and respiratory tract
specimens (99, 1.5%). The source of isolation
correlated with the different species (p <0.001);
notably, non-mirabilis Proteus spp. were much
more likely to be isolated from wounds ⁄ soft-
tissue (263 ⁄ 492, 53% vs. 211 ⁄ 6035, 3%; RR 15.29;
95% CI 13.08–17.87; p <0.0001), and were less
likely to be isolated from urine (165 ⁄ 492, 34%
vs. 5425 ⁄ 6035, 90%; RR 0.37; 95% CI 0.33–0.42;
p <0.0001), in comparison with other species
within the tribe. In total, 1905 non-Proteeae
isolates were obtained as part of polymicrobial
infections that included Proteeae; the most com-
mon were Enterococcus spp. (614, 32%), Escherichia
coli (419, 22%), Staphylococcus aureus (168, 9%),
and Pseudomonas aeuruginosa (121, 6%).
In the incident cohort of 5047 cases, a number
of different demographical and microbiological
aspects were revealed according to the different
species subgroups (Table 1). Non-mirabilis Proteus
spp. consisted of Prot. vulgaris (120 cases), Proteus
penneri (24), and un-speciated Proteus (260). Prov-
idencia stuartii was the most common incident
species in that genus (149 cases), followed
by Providencia rettgeri (72) and un-speciated
Providencia (7). Generally, compared with other
species ⁄ groups, Prot. mirabilis occurred at a much
higher frequency, especially among females, and
was less likely to be hospital-onset or to be part of
a polymicrobial infection (Table 1). Among inci-
dent community-onset isolates (n = 4290), Provi-
dencia spp. were much less likely to be isolated
from outpatients (57 ⁄ 198, 29% vs. 2460 ⁄ 4092,
60%; RR 0.48; 95% CI 0.38–0.60; p <0.0001), and
were much more likely to be isolated from
nursing home residents (92 ⁄ 198, 47% vs.
878 ⁄ 4092, 21%; RR 2.17; 95% CI 1.84–2.54;
p <0.0001), than other Proteeae.
Prot. mirabilis had lower in-vitro rates of resist-
ance to most of the antimicrobial agents tested,
especially b-lactams (Table 2). Overall, 4507 (96%)
of 4697 Proteeae isolates were susceptible to ci-
proﬂoxacin, 4452 (95%) of 4706 to gentamicin, and
4130 (88%) of 4709 to trimethoprim–sulphameth-
oxazole. Although there was no signiﬁcant rela-
tionship between the year of isolation and any
change in trimethoprim–sulphamethoxazole
resistance rates, a signiﬁcantly higher rate of
resistance to ciproﬂoxacin was observed during
the ﬁnal 3 years (2003–2005) of the study than
during the ﬁrst 3 years (2000–2002) (113 ⁄ 2296, 5%
vs. 77 ⁄ 2401, 3%; p <0.01). In contrast, rates of
resistance to piperacillin–tazobactam (25 ⁄ 1842, 1%
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Fig. 1. Age- and gender-speciﬁc incidence of isolation of
Proteeae in the Calgary Health Region. F, female; M, male.
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Fig. 2. Age- and gender-speciﬁc incidence of Proteeae
causing bacteraemia in the Calgary Health Region. F,
female; M, male.
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vs. 102 ⁄ 2198, 5%; p <0.0001) and gentamicin
(96 ⁄ 2301, 4% vs. 158 ⁄ 2405, 7%; p <0.001) were
signiﬁcantly lower in the ﬁnal 3 years of the study.
Cefpodoxime resistance was found in 30 (1%) of
3803 isolates of Prot. mirabilis; 27 of these isolates
tested positive for extended-spectrum b-lactamase
production according to CLSI criteria, and the
remaining three isolates tested positive for AmpC
production.
DISCUSSION
This study represents the ﬁrst population-based
description of the Proteeae, and provides novel
information on the distribution of bacteraemic
and non-bacteraemic isolates. Proteeae were iso-
lated from almost 0.1% of CHR residents ⁄ year in
this study, conﬁrming that these organisms are
relatively common. Nevertheless, they rarely
cause bacteraemia (2.0 cases ⁄ 100 000 ⁄year). To
put this in context, this rate is c. ten-fold lower
than that reported for invasive pneumococcal (20–
22 ⁄ 100 000) and S. aureus (28 ⁄ 100 000) disease
[15–17], but is comparable to rates of Candida
spp. bloodstream infection (2.8 ⁄ 100 000) [18].
The use of population-based methodology is
the strength of this study. Proteeae isolates from
all patients in the region were studied, including
patients in hospitals, physician’s ofﬁces, clinics,
nursing homes and urgent-care centres, and
attempts were made to exclude all isolates
obtained from non-residents [13]. The fact that
all isolates were included, i.e., sampling was not
performed, minimised the risk of selection bias.
Most studies describing infectious diseases typic-
ally involve tertiary-care centres or selected ⁄par-
ticipating laboratories, and are therefore at risk of
selection bias. In addition, such studies rarely
include a representative collection of samples
from community-based laboratories, and may
therefore fail to provide a valid picture of the
overall burden or risk-factors for a particular
disease in a population. For example, a previous
population-based study, which demonstrated that
extended-spectrum b-lactamase-producing E. coli
strains are predominantly agents of commu-
nity-onset disease, provided strong evidence
against the previously held belief, supported by
hospital-based studies, that this was largely a
nosocomial infection [19–21].
Table 1. Features of incident isolates of Proteeae according to species grouping
Species group Incidence ⁄ 100 000 Age (IQR) Female Hospital-onset Bacteraemiaa Polymicrobial aetiology Nursing home
Proteus
mirabilis
(n = 3903)
58.7 69 (39.5–81.8) 2845 (73%) 498 (13%) 98 (3%) 827 (21%) 758 (19%)
Non-mirabilis
Proteus spp.
(n = 404)
6.1 70.7 (46.5–81.8) 233 (58%) 86 (21%) 5 (1%) 229 (57%) 63 (16%)
Morganella
morganii
(n = 512)
7.7 70.4 (47.1–81.5) 267 (52%) 143 (28%) 20 (4%) 193 (38%) 57 (11%)
Providencia spp.
(n = 228)
3.4 72.6 (50.5–83.9) 115 (50%) 30 (13%) 11 (5%) 99 (43%) 92 (40%)
aBacteraemia includes three cases involving Proteus vulgaris, one involving Proteus penneri, one un-speciated Proteus, seven Providencia stuartii and four Providencia rettgeri.
IQR, inter-quartile range.
Table 2. Resistance of Proteeae to common antimicrobial agents
Species group AMC SXT TZP AMP CFZ CRO CXM CAZ GEN NIT CIP
Morganella
morganiia
(n = 512)
490 ⁄ 491
(100%)
68 ⁄ 492
(14%)
16 ⁄ 114
(14%)
491 ⁄ 492
(100%)
491 ⁄ 492
(100%)
1 ⁄ 102
(1%)
99 ⁄ 100
(100%)
31 ⁄ 180
(17%)
35 ⁄ 492
(7%)
363 ⁄ 492
(74%)
14 ⁄ 490
(3%)
Proteus
mirabilis
(n = 3903)
184 ⁄ 3842
(5%)
468 ⁄ 3853
(12%)
99 ⁄ 3835
(3%)
623 ⁄ 3854
(16%)
64 ⁄ 3854
(2%)
30 ⁄ 3838
(1%)
30 ⁄ 3834
(1%)
30 ⁄ 3835
(1%)
205 ⁄ 3849
(5%)
3844 ⁄ 3844
(100%)
131 ⁄ 3842
(3%)
Non-mirabilis
Proteus spp.
(n = 404)
139 ⁄ 142
(98%)
8 ⁄ 144
(6%)
3 ⁄ 54
(6%)
142 ⁄ 144
(99%)
142 ⁄ 144
(99%)
12 ⁄ 42
(29%)
49 ⁄ 52
(94%)
2 ⁄ 57
(4%)
0 ⁄ 144
(0%)
144 ⁄ 144
(100%)
2 ⁄ 144
(1%)
Providencia spp.a
(n = 228)
220 ⁄ 221
(100%)
35 ⁄ 220
(16%)
9 ⁄ 37
(24%)
219 ⁄ 220
(100%)
215 ⁄ 221
(97%)
1 ⁄ 33
(3%)
10 ⁄ 33
(30%)
6 ⁄ 66
(9%)
14 ⁄ 221
(6%)
211 ⁄ 221
(95%)
43 ⁄ 221
(19%)
AMC, amoxycillin–clavulanate; SXT, trimethoprim–sulphamethoxazole; TZP, piperacillin–tazobactam; AMP, ampicillin; CFZ, cefazolin; CRO, ceftriaxone; CXM, cefuroxime;
CAZ, ceftazidime; GEN, gentamicin; NIT, nitrofurantoin; CIP, ciproﬂoxacin.
aThese bacteria produce inducible AmpC b-lactamases, and the clinical relevance of susceptibity to cefazolin, ceftriaxone, cefuroxime and ceftazidime is doubtful.
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The dramatic age-related incidence of isolation
of Proteeae (Fig. 1) probably reﬂects, at least in
part, the high rate of bacteriuria in the elderly. It
should be emphasised that the rates reported in
this study reﬂect the isolation of Proteeae, but do
not necessarily indicate the presence of active
infection requiring treatment. Establishing the
presence of clinically signiﬁcant disease with
isolates associated with non-sterile sites cannot
be achieved through laboratory-based surveil-
lance alone. The major challenge with such
surveillance studies is that rates of isolation of
an organism will be inﬂuenced by the rate of
submission of specimens for culture. As a general
rule, the more severe the infection, the less this
bias will be, and it is therefore probably very
small for invasive or bacteraemic disease [22]. The
observation of a dramatically increased rate of
bacteraemia with increased age (Fig. 2) supports
the hypothesis that age is a true risk-factor for
development of Proteeae infections.
An advantage of the study was that it was
possible to directly compare features among the
different species ⁄ groups of the Proteeae in a
single study. The ﬁndings that Prot. mirabilis
was proportionally more likely to be isolated
from urine and females in the community, and to
exhibit increased susceptibility to antimicrobial
agents, is consistent with current knowledge of
the Proteeae [1]. Several studies have suggested a
role for Prov. stuartii as an important agent in
infections among nursing home residents, partic-
ularly urinary tract infections [3,4]. While the
present data revealed a proportionally higher
isolation rate for Providencia spp. among nursing
home residents, it is notable that 68 (46%) of 149
isolates were obtained from acute-care hospitals
and other community settings. In a review of 132
cases in a tertiary-care hospital, Kim et al. [11]
reported that M. morganii was proportionally the
most common cause of bacteraemia caused by
Proteeae (46%), followed by Prot. mirabilis (31%)
and Prot. vulgaris (15%). In contrast, the present
study found that Prot. mirabilis was responsible
for 73% of bacteraemias and that M. morganii
caused only 15% of such cases. While the differ-
ences in the relative occurrence of these species
could be caused, at least in part, by intrinsic
differences between the Canadian and Korean
populations, the high rate of M. morganii infec-
tions seen in the Korean study may reﬂect its
hospital-based design.
The observation that Prot. mirabilis had much
lower rates of in-vitro resistance to most of the
antimicrobial agents tested than other members of
the Proteeae is consistent with existing know-
ledge [1]. The rates of ciproﬂoxacin and gentam-
icin resistance among Proteus spp. were lower [6]
than those in other multicentre surveillance data
obtained from the MYSTIC programme. Most
members of the Proteeae encode chromosomal
broad-spectrum b-lactamases that confer wide-
spread penicillin and cephalosporin resistance.
Although this is not the case for Prot. mirabilis,
several reports have documented the emerging
importance of acquired extended-spectrum
b-lactamase production in this species [7,10].
Extended-spectrum b-lactamase production is
uncommon among Prot. mirabilis isolates in the
Calgary region. However, the increasing annual
rates of resistance to ciproﬂoxacin among the
isolates is a concern for the future.
In conclusion, the results of this study revealed
that isolation of members of the Proteeae is
common in the Calgary region, and that commu-
nity-based patients, females and the elderly are at
highest risk, but that the Proteeae cause bacterae-
mic disease infrequently. The study highlighted
the importance of population-based studies in
accurately deﬁning the epidemiology of an infec-
tious disease.
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